Negative Allosteric Modulators: New Hope for Anxiety?

Zurich, February 4, 2026 — A new approach to tackling anxiety and fear-related disorders, including posttraumatic stress disorder, is showing promise in early research. Scientists have discovered that modulating a specific brain receptor—metabotropic glutamate receptor 7, or mGlu7—can weaken the hold of painful memories, potentially offering a more targeted and durable treatment than current options.

Rewriting Fear: New Target for Anxiety Treatment

Preclinical data suggests a novel drug targeting mGlu7 could alter how the brain processes fear, offering a potential breakthrough for those with anxiety and trauma.

• Targeting mGlu7 receptors may disrupt the reconsolidation of fear memories.
• The drug ADX71743 showed promise in rat models, impacting fear responses.
• Findings in rodent models were mirrored in human brain tissue samples.
• Current anxiety treatments often require continuous use and can have side effects.

Can we actually *erase* painful memories? Not quite, but research suggests we can weaken their emotional grip. By interfering with the brain’s process of reconsolidating fear memories—essentially, the way memories are restabilized when recalled—scientists believe they’ve found a new avenue for treating anxiety and trauma.

The research, conducted by the Center for Psychiatric Neurosciences in Switzerland, focused on ADX71743, a selective mGlu7 negative allosteric modulator. Data revealed that modulating mGlu7 could selectively interfere with fear memory reconsolidation.² This process, where memories become malleable again after being recalled, is increasingly recognized as a key intervention point for anxiety and trauma-related conditions.

In the study, administering ADX71743—either directly into the lateral amygdala (a brain region crucial for processing fear) or systemically—disrupted fear memory reconsolidation in rats. This disruption was specific to the conditioned stimulus, meaning it targeted the fear memory itself, and occurred within a defined timeframe after recall. Importantly, it significantly reduced the reinstatement of fear responses.

The findings suggest a “time-limited pharmacological intervention,” meaning a drug taken in conjunction with memory recall could provide more lasting relief than continuous medication, according to Ron Stoop, PhD, paper author and assistant professor at the Center for Psychiatric Neurosciences.¹

Further analysis of electrophysiology supported the idea that the drug was effectively engaging the mGlu7 target. ADX71743 modulated glutamatergic transmission at synapses connecting the thalamus to the amygdala—critical pathways for fear learning. In baseline conditions, the drug increased spontaneous excitatory signaling, and under high-stimulation conditions, it prevented long-term potentiation, a cellular process associated with memory formation.

Remarkably, similar synaptic effects were observed in human brain tissue models, providing early validation for translating these findings to human treatments. The mGlu7 receptor is highly expressed throughout the central nervous system and plays a significant role in emotional reactivity, stress response, learning, memory, and attention.

“Anxiety and stress-related disorders are incredibly common, yet many patients don’t experience complete or lasting relief from existing therapies,” explained Tim Dyer, chief executive officer of Addex, in a press release. “Current drugs often target symptoms and require continuous use, like benzodiazepines, which carry risks of tolerance, dependence, and relapse.” He emphasized that targeting memory reconsolidation with mGlu7 modulators represents a fundamentally different therapeutic approach.

The mGlu7 receptor has long been considered a promising target for a range of psychiatric disorders, including posttraumatic stress disorder, obsessive-compulsive disorder, anxiety, depression, substance use disorder, and schizophrenia.

References

1. Addex announces publication of preclinical data supporting potential of mGlu7 negative allosteric modulators to transform anxiety and fear-related disorder treatment. Press release. February 3, 2026. Accessed February 4, 2026. https://www.globenewswire.com/news-release/2026/02/03/3230712/0/en/Addex-Announces-Publication-of-Preclinical-Data-Supporting-Potential-of-mGlu7-Negative-Allosteric-Modulators-to-Transform-Anxiety-and-Fear-Related-Disorder-Treatment.html

2. Ciobanu AC, Caseiro DM, Niu R, et al. Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue. Mol Psychiatry. 2026;31:976–986.